Internal validation
PROSTATE CANCER
On the validation data set, the AUCs were 0.88 (95% CI 0.81–0.95) for Model 1, 0.90 (95% CI 0.84–0.96) for Model 2, and 0.88 (95% CI 0.82–0.95) for Model 3. Delong’s test showed that the prediction of Model 2 was significantly higher as compared with Model 1 (P = 0.04), but did not substantially different than Model 3 (P = 0.05). A nomogram based on the combination of Scoring 2, age, and PSAD was constructed, in which points from each variable are added and a straight line from the total point score shows the probability of harboring csPCa (Fig. 
Construction of a nomogram for predicting the probability of clinically significant prostate cancer. bpMRI, biparametric magnetic resonance imaging; PSAD, prostate-specific antigen density